Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Significant Decline in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 4,327 shares, a decline of 52.4% from the November 30th total of 9,085 shares. Based on an average daily trading volume, of 79,708 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are sold short. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 79,708 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. HC Wainwright increased their price target on Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research note on Monday. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Barinthus Biotherapeutics currently has an average rating of “Hold” and an average price target of $4.00.

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC acquired a new position in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 37,450 shares of the company’s stock, valued at approximately $36,000. HighTower Advisors LLC owned about 0.09% of Barinthus Biotherapeutics at the end of the most recent reporting period. Institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Trading Up 0.4%

Barinthus Biotherapeutics stock traded up $0.00 during trading hours on Friday, reaching $0.70. 159,885 shares of the stock were exchanged, compared to its average volume of 67,689. The stock has a 50 day moving average of $0.90 and a two-hundred day moving average of $1.11. The company has a market cap of $28.75 million, a P/E ratio of -0.37 and a beta of -0.67. Barinthus Biotherapeutics has a twelve month low of $0.64 and a twelve month high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings results on Friday, November 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.09. On average, analysts expect that Barinthus Biotherapeutics will post -1.38 earnings per share for the current fiscal year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.